Follow-up regimes for sick-listed employees: A comparison of nine north-western European countries.

European countries comparative study sick-pay sickness absenteeism sickness benefit

Journal

Health policy (Amsterdam, Netherlands)
ISSN: 1872-6054
Titre abrégé: Health Policy
Pays: Ireland
ID NLM: 8409431

Informations de publication

Date de publication:
07 2022
Historique:
received: 16 03 2021
revised: 02 03 2022
accepted: 07 05 2022
pubmed: 17 5 2022
medline: 22 6 2022
entrez: 16 5 2022
Statut: ppublish

Résumé

The Covid-19 pandemic has revealed the importance of social protection systems, including income security, when health problems arise. The aims of this study are to compare the follow-up regimes for sick-listed employees across nine European countries, and to conduct a qualitative assessment of the differences with respect to burden and responsibility sharing between the social protection system, employers and employees. The tendency highlighted is that countries with shorter employer periods of sick-pay typically have stricter follow-up responsibility for employers because, in practice, they become gatekeepers of the public sickness benefit scheme. In Germany and the UK, employers have few requirements for follow-up compared with the Nordic countries because they bear most of the costs of sickness absence themselves. The same applies in Iceland, where employers carry most of the costs and have no obligation to follow up sick-listed employees. The situation in the Netherlands is paradoxical: employers have strict obligations in the follow-up regime even though they cover all the costs of the sick-leave themselves. During the pandemic, the majority of countries have adjusted their sick-pay system and increased coverage to reduce the risk of spreading Covid-19 because employees are going to work sick or when they should self-quarantine, except for the Netherlands and Belgium, which considered that the current schemes were already sufficient to reduce that risk.

Identifiants

pubmed: 35577620
pii: S0168-8510(22)00104-X
doi: 10.1016/j.healthpol.2022.05.002
pmc: PMC9085445
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

619-631

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Références

Soc Sci Med. 2011 Dec;73(11):1608-17
pubmed: 22014419
Eur J Public Health. 2014 Aug;24(4):663-6
pubmed: 24919693
J Occup Rehabil. 2009 Dec;19(4):419-26
pubmed: 19760488
Int J Health Serv. 2010;40(1):1-22
pubmed: 20198801
Int J Health Serv. 2012;42(2):235-55
pubmed: 22611653
Qual Health Res. 2007 Oct;17(8):1103-16
pubmed: 17928482
Occup Environ Med. 2004 Oct;61(10):867-9
pubmed: 15377774
Eur J Health Econ. 2016 Jul;17(6):693-709
pubmed: 26280132
J Econ Perspect. ;29(2):151-72
pubmed: 28443648
Br J Ind Med. 1986 Aug;43(8):529-36
pubmed: 3730302

Auteurs

Solveig Osborg Ose (SO)

SINTEF Health Services Research, Klæbuveien 153, Trondheim 7037, Norway. Electronic address: solveig.ose@sintef.no.

Silje Lill Kaspersen (SL)

SINTEF Health Services Research, Klæbuveien 153, Trondheim 7037, Norway.

Taina Leinonen (T)

Finnish Institute of Occupational Health, Finland.

Suzanne Verstappen (S)

Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, United Kingdom.

Angelique de Rijk (A)

Department of Social Medicine, Faculty of Health Medicine and Life Science, Care and Public Health Research Institute, Maastricht University, The Netherlands.

Slavina Spasova (S)

European Social Observatory, Belgium.

Sara Hultqvist (S)

Lund University, Sweden.

Iben Nørup (I)

Aalborg University, Denmark.

Jón R Pálsson (JR)

Confederation of Icelandic employers, Iceland.

Andreas Blume (A)

Ruhr Universität Bochum, Germany.

Mike Paternoga (M)

HR&C GmbH, Germany.

Jorid Kalseth (J)

SINTEF Health Services Research, Klæbuveien 153, Trondheim 7037, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH